Clinical Trial Detail

NCT ID NCT02603887
Title Pembrolizumab for Smoldering Multiple Myeloma (SMM)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

multiple myeloma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.